. The main function of the Hippo pathway is to negatively regulate the activity of Yes-associated protein (YAP) and transcriptional co-activator with PDZbinding motif (TAZ) -two homologous transcriptional co-activators that are the main downstream mediators of the Hippo pathway 10 . When activated, YAP and TAZ promote cell proliferation and inhibit cell death; YAP and TAZ are hyperactivated in many human malignancies 7, [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] . Therapeutic intervention for cancer would thus involve reducing or inhibiting the oncogenic function of YAP and/or TAZ. However, to date, few smallmolecule inhibitors have been discovered that target the Hippo pathway, and a prevalent view is that most Hippo pathway signalling components are not conventional drug targets. Indeed, YAP and TAZ are transcriptional co-activators with no known catalytic activity. Moreover, no known upstream regulators that specifically promote YAP and TAZ activity have demonstrated enzymatic activity 6, 7 . Thus, inhibiting the function of YAP and TAZ may require targeting protein-protein interactions. A further complication is that YAP and TAZ are required for tissue repair and regeneration in some contexts [22] [23] [24] [25] [26] [27] [28] [29] [30] , raising questions as to whether systemic and chronic manipulation of Hippo signalling might have potential deleterious side effects on normal tissue function and homeostasis. However, transient activation of YAP and TAZ may help to promote tissue repair and regeneration in the context of injury 28, 29 . These two faces of the Hippo signalling pathway suggest that the identification and proper application of small-molecule modulators of Hippo signalling may provide exciting new approaches for cancer therapy and for regenerative medicine.
Overview of the Hippo pathway
The Hippo pathway relays signals from the plasma membrane into the nucleus, where it regulates the expression of a series of target genes that control diverse cellular processes such as proliferation, survival and differentiation [1] [2] [3] [4] [5] [6] . In this regard, Hippo signalling is similar to other well-known signal transduction pathways such as the 
Transcriptional co-activators
Proteins that stimulate gene expression but that cannot bind to DNA itself and are instead recruited to DNA by binding to another DNA-binding transcription factor.
epidermal growth factor (EGF), transforming growth factor-β (TGFβ) or WNT signalling pathways. However, in contrast to these pathways, the Hippo pathway does not appear to have dedicated extracellular signalling peptides and receptors, but is instead regulated by a network of upstream components and mechanisms, many of which are also involved in regulating cell adhesion and cell polarity 3, 6, 31 . Nevertheless, the Hippo pathway bears considerable resemblance to other canonical signal transduction pathways as many upstream regulators feed into the core of the pathway, which is composed of two serine/threonine kinases known as the Hippo and Warts kinases in fruitflies [32] [33] [34] [35] [36] [37] [38] ; Hippo kinase is known as mammalian STE20-like protein kinase 1 (MST1) and MST2 in humans, whereas Warts kinase is known as large tumour suppressor homolog 1 (LATS1) kinase and LATS2 kinase in humans [38] [39] [40] [41] . These kinases and their essential roles in growth control were first discovered in Drosophila melanogaster and they function together in a novel signalling pathway that has been named the 'Hippo pathway' after one of its founding members 32 . Since the discovery of the Hippo and Warts kinases, many additional components of the Hippo pathway have been identified, and a complex signalling network has emerged that integrates multiple upstream inputs from the plasma membrane into the nucleus (FIGS 1, 2) . In this Review, we largely refer to Hippo signalling components using the mammalian nomenclature, and the D. melanogaster components are listed in The Hippo signalling pathway. The core of the Hippo pathway comprises a highly conserved signalling module that functions similarly in mammals and in D. melano gaster. This pathway contains the serine/threonine kinases MST1, MST2, LATS1 and LATS2 , the scaffolding protein Salvador homolog 1 (SAV1; which interacts with MST1 and MST2) 42, 43 and the scaffolding proteins MOB kinase activator 1A (MOB1A) and MOB1B (which interact with LATS1 and LATS2, respectively) 44 , the transcriptional co-activators YAP and TAZ 45 , and the TEA domain-containing sequence-specific transcription factors TEAD1 to TEAD4 (FIG. 1) . YAP and TAZ are transcriptional co-activators that are not able to bind to DNA themselves but form complexes with TEADs [46] [47] [48] [49] [50] as their main partners; they also bind to other transcription factors such as SMADs [51] [52] [53] , T-box transcription factor 5 (TBX5) 54, 55 , RUNT-related transcription factor 1 (RUNX1) and RUNX2 56 as well as p73 (REF. 57) to regulate gene expression.
The Hippo pathway is considered to be in the active state when the MST and LATS kinases are active (FIG. 1a) . The MST kinases -in complex with SAV1 -phosphorylate and activate the LATS kinases and MOB1 co factors 35, [58] [59] [60] [61] , which in turn phosphorylate their downstream targets YAP and TAZ 11, 21, 45, [62] [63] [64] [65] . Phosphorylation of YAP and TAZ results in their nuclear export, cytoplasmic retention and β-TRCP (β-transducin repeat-containing E3 ubiquitin protein ligase)-dependent degradation by the proteasome 11, 21, 62, 63, [66] [67] [68] [69] . Instead of binding to YAP and TAZ, the TEADs then form complexes with the transcription cofactor vestigial-like protein 4 (VGL4), which represses target gene expression 70, 71 . Thus, when the Hippo pathway is activated, YAP and TAZ activity is inhibited, and YAP-and TAZ-driven gene expression is suppressed. Conversely, when the Hippo pathway is deactivated, YAP and TAZ accumulate in the nucleus, where they drive gene expression by forming complexes with TEAD and other transcription factors [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [72] [73] [74] [75] [76] (FIG. 1b) .
Thus, the Hippo pathway acts primarily by inhibiting the nuclear functions of YAP and TAZ.
Regulation of activity.
A key question concerning the Hippo pathway relates to the signals and mechanisms that regulate its activity and, ultimately, that of YAP and TAZ. To date, over 20 regulators have been identified that intersect with the core of the Hippo pathway at different levels [1] [2] [3] [4] [5] [6] 31 (FIG. 2) . In mammals, at least four interconnected upstream branches regulate the Hippo pathway: the Crumbs homolog (CRB) complex; regulators that act upstream of the MST kinases; the actin cytoskeleton; and the adherens junction. Each of these inputs is described below.
The CRB complex contains CRB proteins, which are transmembrane proteins that localize to apical junctions and are required to specify the apical plasma membrane domain 77 . CRB proteins have short intracellular domains with protein docking sites that assemble multiprotein complexes that function in cell polarity and also regulate the Hippo pathway [78] [79] [80] [81] [82] . Most prominently for its regulation of the Hippo pathway in mammals, the CRB complex recruits members of the angiomotin (AMOT) family of adaptor proteins that directly bind to components of the Hippo pathway. Initial reports showed that AMOT inhibits the nuclear localization of YAP by directly binding to YAP and by activating LATS kinases to promote YAP phosphorylation and nuclear exclusion 78, [83] [84] [85] [86] [87] [88] . However, a recent report has shown, using knockout mice, that in vivo AMOT is required for the YAP-dependent overgrowth of neurofibromin 2 (Nf2; also known as Merlin)-mutant mouse livers, that AMOT promotes the nuclear localization of YAP and that it forms a functional complex with YAP and TEADs on target gene DNA 89 . AMOT may thus have both growth-promoting and growth-suppressing functions depending on the cellular and molecular context. However, the reasons for these seemingly paradoxical results are not known and further analysis is required.
A second branch of the Hippo pathway consists of kinases and other regulators that modulate the activity of the MST kinases. These include the TAO (thousand and one amino acid protein) kinases and the cell polarity kinase MAP/microtubule affinity-regulating kinase 1 (MARK1; also known as PAR1), which directly phosphorylate MST kinases and regulate their activity [90] [91] [92] . In addition, MSTs are regulated by the adaptor protein KIBRA (kidney and brain protein; also known as WWC1) [93] [94] [95] , and in D. melanogaster the Hippo kinase is also regulated by the adaptor protein Expanded 96 . A third branch of the Hippo pathway is defined by an as yet poorly understood signalling mechanism that is mediated by the actin cytoskeleton. Here, the mechanical properties of the extracellular matrix and cell matrix Nature Reviews | Drug Discovery attachment regulate the localization and activity of YAP and TAZ, through a process that requires F-actin and that is also present in D. melanogaster [97] [98] [99] [100] [101] . In addition, G protein-coupled receptors (GPCRs) that relay signals from soluble extracellular cues such as lysophosphatidic acid and sphingosine-1-phosphate regulate YAP and TAZ activity through RHO GTPases, which are likely to affect YAP and/or TAZ via modulation of the actin cytoskeleton [102] [103] [104] . Thus, pathways that regulate the structure of the actin cytoskeleton -for example, by activating RHO signalling -affect the Hippo pathway. However, although it is generally appreciated that F-actin intersects the pathway downstream of the MST kinases, the exact mechanism by which this occurs is not known and it may involve LATS-dependent and -independent regulation of YAP and TAZ [97] [98] [99] [100] [101] 105 . A fourth branch of the inputs to the Hippo pathway emanates from the adherens junction. Engagement of E-cadherin at adherens junctions suppresses the nuclear localization and activity of YAP by regulating MST activity 106 . In addition, the E-cadherin-associated protein α-catenin regulates YAP directly by sequestering YAP-14-3-3 protein (also known as YWHAQ) complexes in the cytoplasm 107, 108 . Furthermore, members of the junction-associated Ajuba protein family directly inhibit LATS kinase activity 109 . In D. melanogaster, the related Zyxin protein also regulates Warts levels 110 . Whether these adherens junction-associated regulators of the Hippo pathway act independently of each other or whether they function coordinately to regulate Hippo signalling is not yet known. In addition, crosstalk among the different regulatory branches is very likely to exist. For example, CRB and adherens junctions regulate the structure of the actin cytoskeleton, and polarity proteins and junction proteins regulate each other [111] [112] [113] [114] . In addition to these four major branches of the upstream regulators of Hippo signalling, there are several other proteins that modulate the activity of Figure 1 | The core of the Hippo signalling pathway and its mode of action. Schematics of the core pathway components and how they interact are depicted. a | When the Hippo pathway is on, mammalian STE20-like protein kinase 1 (MST1) or MST2 phosphorylate Salvador homolog 1 (SAV1), and together they phosphorylate and activate MOB kinase activator 1A (MOB1A), MOB1B, large tumour suppressor homolog 1 (LATS1) kinase and LATS2 kinase, which then phosphorylate Yes-associated protein (YAP) and transcriptional co-activator with PDZ-binding motif (TAZ). Phosphorylated YAP and TAZ are sequestered in the cytoplasm by the 14-3-3 protein and shunted for proteasomal degradation. As a result, the TEA domain-containing sequence-specific transcription factors (TEADs) associate with the transcription cofactor vestigial-like protein 4 (VGL4) and suppress target gene expression. b | When the Hippo pathway is off, the kinases MST1, MST2, LATS1 and LATS2 are inactive, so YAP and TAZ are not phosphorylated and instead accumulate in the nucleus where they displace VGL4 and form a complex with TEADs, which promotes the expression of target genes. Nature Reviews | Drug Discovery [124] [125] [126] [127] [128] , casein kinase 1 (CSNK1) and β-TRCP 68, 69 . They also include proteins that interact with the upstream kinase complexes, such as the RAS association domain-containing family proteins (RASSFs) [129] [130] [131] , protein phosphatase 2A (PP2A) 132 , salt-inducible kinases (SIKs) 133 , Merlin 96, 134 , Scribble and the Scribble-associated proteins discs large (Dlg) and lethal giant larvae (Lgl) 81, [135] [136] [137] [138] . In D. melano gaster, Scribble, Dlg and Lgl form a module that regulates cell polarity and establishes the basolateral domain, which indicates that the Hippo pathway is independently modulated by several junctional complexes 3, 31, 111 . The D. melanogaster Hippo pathway is also regulated by a signalling axis from the atypical cadherin FAT, which regulates the levels and activity of Warts kinases 2, 3, 31 . However, it is not clear whether FAT homologs are involved in the regulation of the vertebrate Hippo pathway 139 .
Tissue-specific pathway regulation. Although the net effect of deregulated YAP and TAZ activity in many tissues is similar, YAP and TAZ activity appears to be controlled by different regulatory mechanisms in different tissues. For example, whereas the MST kinases are essential for inhibiting YAP and TAZ in the liver [140] [141] [142] [143] , intestine 144 , pancreas 145, 146 and heart 147 , they appear to be dispensable in the skin 107 . Presumably, other negative regulatory mechanisms predominate in the skin, and sequestration via α-catenin and AMOT have been suggested to circumvent the need for phosphorylation by LATS kinases 107, 108 . Further evidence of cell-type specificity in Hippo pathway regulation comes from the observations that the MST kinases are largely dispensable in mouse embryonic fibroblasts (MEFs) 140, 142 , whereas the LATS kinases are essential for inhibiting the activities of YAP and TAZ 148 . Tissue-specific requirements for upstream components are also observed in D. melanogaster, in which FAT signalling is dominant in imaginal discs but has no significant effect in the ovarian follicle cell epithelium [149] [150] [151] [152] [153] [154] [155] . Likewise, Merlin has minor effects in imaginal discs but is a major regulator of the Hippo pathway in follicle cells 149, 150, [156] [157] [158] [159] [160] .
The Hippo pathway in growth control and cancer The dramatic overgrowth phenotypes caused by the loss of Hippo pathway activity in D. melanogaster first led to the idea that this pathway may be important in the control of organ growth and that it acts as a tumour suppressor in vertebrates. Indeed, many studies have now shown that loss of Hippo signalling or hyperactivation of YAP and TAZ promotes growth and cell pluripotency depending on the tissue context. Thus, loss of Hippo pathway activity in mouse models causes overgrowth of various organs such as the liver and heart, and it can lead to the development of cancer in the liver, skin and intestine. Below, we highlight the phenotypes associated with loss of pathway activity in genetically engineered animal models, discuss cellular events that are controlled by YAP and TAZ, and summarize the evidence for a role of hyperactive YAP and TAZ in human cancer.
Hippo signalling in growth control. A predominant function of the Hippo pathway is in regulating progenitor cell proliferation and organ size. In D. melanogaster, loss of function of the Hippo or Warts kinases, or overexpression of Yorkie (the D. melanogaster homolog of YAP and TAZ), during development results in severely overgrown imaginal discs, which leads to dramatic overgrowth of the corresponding adult structures 32-38,45 (FIG. 3a,b ). These overgrowths arise because mutant cells have two defects. First, cell proliferation is dysregulated; they proliferate faster than wild-type cells and continue to proliferate when wild-type cells stop proliferating, after tissues have reached their proper size. Second, these mutant cells are resistant to the apoptotic signals that are induced to eliminate the extra cells. The combination of these defects therefore results in the production of excess cells that cannot be eliminated, leading to increased organ size.
Similarly, in mice, YAP overexpression or loss of MST or LATS kinase activities increases liver and heart size by increasing cell number 11, [140] [141] [142] [143] 147, 161, 162 (FIG. 3c,d ).
However, the relationship between Hippo signalling and organ size is not absolute. In some tissues such as the skin and intestine, overexpression or activation of YAP causes an enlargement of the stem cell compartment, in part owing to a block in differentiation, but it does not lead to an overall increase in organ size 12, 107, 163 . This may be due to the cellular composition of these tissues as they continuously undergo a stem-cell-driven renewal programme. Thus, the general conclusion from genetic studies of the Hippo pathway in mice and fruitflies is that YAP and Yorkie drive cell proliferation and tissue growth. However, they may not drive growth in every tissue, and they also have other functions apart from regulating tissue growth, although these functions appear to be minor and related to cellular differentiation 1, 164, 165 . Several direct downstream target genes of the Hippo pathway have been identified and include genes such as cyclins, growth factors and inhibitors of apoptosis that are involved in cell proliferation, cell survival and stem cell functions, among others. In D. melanogaster, a combination of chromatin immunoprecipitation followed by sequencing (ChIP-seq) and RNA sequencing (RNA-seq) for Yorkie and the TEAD protein Scalloped, showed that Yorkie and Scalloped regulate most of the genes that are expressed in imaginal discs, making them more akin to general transcriptional activators 166 . At present, however, it is not completely understood how YAP, TAZ and Yorkie drive cell proliferation and tissue growth; this is likely to involve the regulation of many direct target genes, some of which directly affect growth and survival, whereas others indirectly affect these processes via global regulation of metabolism and other cell ular processes 21, [166] [167] [168] . . Elevated levels and nuclear localization of YAP and, in some cases, TAZ have been reported in the majority of solid cancers, which suggests that there is widespread deregulation of Hippo signalling in human neoplasia 7, 11, 12, [15] [16] [17] [18] [19] [20] [21] . Abnormally elevated YAP levels and nuclear localization occur in various human cancers including liver, lung, breast, skin, colon and ovarian cancer 7, 11, 12, [15] [16] [17] [18] [19] [20] [21] . Mouse models have shown that in the liver, skin and colon the attenuation of Hippo signalling or overexpression of YAP is sufficient to promote tumour formation 11, 12, 15, 107, [140] [141] [142] [143] (FIG. 3e,f) . The exact mechanisms involved in the transformation of normal cells to malignant tumour cells by deregulated YAP and TAZ are not known but are likely to involve enhanced cell proliferation and survival coupled with the acquisition of additional cancer cell phenotypes such as cancer stem cell characteristics, epithelial to mesenchymal transition (EMT), drug resistance and inhibition of senescence, as these are all YAP-and TAZ-promoted activities that are abnormally regulated in tumour cells (FIG. 4) .
The association of Hippo signalling with stem cell properties has recently been extended to include cancer stem cells. In breast cancer, TAZ has been shown to be a potent stimulator of cancer stem cells in vitro 137 . Overexpression of TAZ increases the ability of MFC10A cells to form mammospheres, which indicates that TAZ enhances the proportion of MCF10A cells with stem cell properties. Conversely, knockdown of endogenous TAZ inhibits mammosphere formation. TAZ is overexpressed in approximately 85% of high-grade human breast cancers, and there is evidence for gene amplification in 15-20% of these cases 137 . Taken together, these results indicate that the activation of TAZ is a major event associated with the initiation and/or progression of breast cancer. By contrast, according to a report by Cordenonsi et al. 137 , YAP does not appear to be effective in promoting cancer stem cell characteristics. However, other studies support a role for YAP in promoting cancer-like properties in non-transformed mammary epithelial cells 15 . Given that YAP and TAZ promote pluripotency in other stem cell contexts, it is likely that their hyperactivation also contributes to the expansion, survival and selfrenewal of cancer stem cells in other malignancies.
In addition to their self-renewal capacity, cancer stem cells are associated with EMT -a feature that is commonly observed in high-grade tumours and metastases. Overexpression of YAP and/or TAZ can lead to the acquisition of a mesenchymal phenotype in mammary epithelial cells, which suggests that Hippo signalling may have important roles in the suppression of EMT 15, 62, 137 . Indeed, the loss of cell polarity determinants such as Scribble leads to reduced Hippo pathway activity, activation of YAP or TAZ, EMT and the expansion of cancer stem cells 137 . Thus, YAP and/or TAZ activation via loss of cell polarity may engage a positive feed-forward loop in which YAP and/or TAZ promote EMT and the loss of cell polarity, which then further activates YAP and TAZ. Importantly, hyperactivation of TAZ has been associated with EMT and high-grade tumours in human breast cancer and in glioma 137, 169 . Cancer stem cells are commonly resistant to chemotherapeutic agents, and several studies have recently indicated that hyperactivation of YAP and/or TAZ contributes to this resistance 15, [170] [171] [172] . Increased cell survival mediated by the suppression of apoptosis is one feature of Hippo pathway inactivation as well as YAP and/or TAZ hyperactivation 11, 15, 42, 43 . Several mechanisms contribute to this suppression, including transcriptional upregulation of pro-survival factors such B cell lymphoma 2 (BCL-2) family members 173 . In addition, it has been reported that connective tissue growth factor (CTGF) and cysteine-rich angiogenic inducer 61 (CYR61) -targets of YAP and TAZ -inhibit apoptosis in liver cells 174, 175 and are responsible for taxol resistance in breast cancer cells 172 . Other mechanisms are likely to contribute to YAP-and/or TAZ-mediated drug resistance, including their ability to promote EMT and stem cell properties 176 , both of which are associated with increased resistance to chemotherapy in various tumours and cell lines 177 . In summary, deregulated YAP and TAZ activity promotes multiple cancer cell phenotypes beyond simply driving cell proliferation, which suggests that targeting YAP and TAZ may inhibit the phenotypes of cancer cells at many levels (FIG. 4) .
Mechanisms of Hippo pathway deregulation in cancer.
The levels and nuclear localization of YAP and TAZ are elevated in many human cancers, and YAP and TAZ promote the acquisition of several important cancer cell phenotypes. However, the mechanism of Hippo pathway deregulation as well as YAP and TAZ activation in human cancers is not well understood. This knowledge gap is important because insight into those molecular mechanisms that are altered and responsible for elevated YAP and/or TAZ activity in cancer would be beneficial for the development of therapies targeting the Hippo pathway. Few germline or somatic mutations in components of the Hippo pathway have been discovered in targeted and whole-genome sequencing efforts to date, which suggests that these may be generally uncommon events 7 . One exception to this observation is the NF2 locus. NF2 encodes the tumour suppressor protein Merlin, which regulates the Hippo pathway by modulating the activity of the LATS kinases to promote their localization to the plasma membrane 96, 134, 178 . NF2 is mutated with a high frequency in neurofibromatosis, a condition that is characterized by malignant peripheral nerve sheath tumours, and it is thus a bona fide tumour suppressor gene 179, 180 . Loss of Merlin as well as the Hippo pathway components LATS2 or SAV1 is also frequently observed in malignant mesothelioma 181 . It is not understood why NF2 and LATS2 mutations are common in neurofibromatosis and mesothelioma but uncommon in other human cancers, despite the widespread deregulation of YAP and TAZ in human 7, 182 , despite the ability of such mutations to drive tumour formation in mouse models of cancer and to confer tumour properties onto non-tumorigenic human cell lines 11, 12, 15 . One possibility is that mutant YAP or TAZ may not confer a growth advantage in human cancers because mutant forms of these proteins may also initiate as yet unknown growth-inhibitory mechanisms, or because they may still be kept in check by mechanisms that act independently of LATS kinases -for example, by actin-mediated regulation of YAP and TAZ 105 .
In support of the latter hypothesis (that is, mutant YAP and TAZ are kept in check by mechanisms other than those involving LATS kinases), YAP and TAZ are found to be genomically amplified in several human cancers including oral cancers, intracranial ependymomas, hepatocellular carcinomas, gliomas and mammary tumours 15, 16, 19, [183] [184] [185] . The frequency of amplification is variable, with high occurrence observed in oral cancers and ependymomas and relatively low frequencies observed in hepatocellular carcinomas and breast cancer. By contrast, approximately 50% of human liver cancers display elevated YAP levels 20 , and TAZ overexpression is observed in over 80% of breast cancers 18, 137 . These findings imply that amplification is a common mechanism in some human cancers but that other mechanisms predominate in other cancers. The exact nature of these other mechanisms is currently not known, but may include promoter methylation and epigenetic silencing of the MST and LATS kinases 186-189, or the expression and/or upregulation of proteins that control YAP transcription [190] [191] [192] [193] or stability 192 . Hence, current evidence suggests that multiple mechanisms contribute to the deregulation of YAP and TAZ in human cancers, including promoter hypermethylation, mutation and amplification. Importantly, although specific defects that deregulate the Hippo pathway in many cancers are not known, the core components of the pathway are largely unaffected by irreversible mutations or genetic aberrations 7 . Hence, at least in principle, these observations provide the opportunity for pharmaceutical interventions to reactivate or restore Hippo pathway function, thereby inhibiting the oncogenic activities of YAP and TAZ.
Modulating the Hippo pathway for cancer therapy. Given the association of elevated and hyperactive YAP and TAZ with many cancers, direct or indirect attenuation of either of these proteins represents a rational and novel targeted approach for the treatment and prevention of human malignancies. In this section, we discuss recent preclinical findings that support efforts directed towards the development of new therapies targeting the Hippo pathway for the prevention and treatment of malignancies.
Several lines of evidence from mouse and in vitro models show that reducing YAP activity is effective in limiting the growth of tumour cells and preventing tumour formation. First, Nf2 deletion in mice induces liver tumour formation; however, simultaneous deletion of Yap specifically in the liver completely suppresses the formation of liver tumours 178 . Importantly, reducingbut not eliminating -Yap gene dosage to 50% results in a similar level of suppression, which indicates that partial inhibition of YAP is effective in preventing tumour formation in this model 178 . In addition, expression of a dominant negative version of TEAD2 (that lacks the DNA binding domain but can still bind to YAP) abolished hepatomegaly and the development of liver cancer in an Nf2-mutant mouse model 194 . A dosage effect for YAP was also seen in a mouse model of colon cancer in which the kinases Mst1 and Mst2 were conditionally deleted in the intestinal epithelium with villin-Cre 144 . By 3 months of age, these mice developed colonic adenomas, which are associated with disruption of the normal colonic tissue architecture resulting from the hyperactivation of YAP. Both of these phenotypes were effectively suppressed by the removal of a single Yap allele 144 . Hence, these two studies show that reducing YAP dosage is effective in preventing tumour formation in situations that are predisposed to YAP activation. Thus, therapeutics that target YAP may not need to fully block YAP activity for efficacy, thereby reducing the potential for negative side effects.
Although these results are encouraging, it has not yet been established whether reducing YAP dosage after tumour formation will cause a reduction in tumour burden. In addition, these studies activate YAP by mechanisms that have not been documented in the corresponding human cancers. Hence, it will be important to test whether reducing the activity of YAP or TAZ is effective using relevant genetically engineered mouse models that more closely recapitulate human cancer. Another issue of concern is the lack of a complete understanding of the long-term consequences of YAP and/or TAZ inhibition on normal and cancerous tissues. It has been shown that deletion of YAP in the mouse intestine can lead to WNT hypersensitivity with subsequent enhanced stem cell expansion and hyperplasia induced upon injury, which suggests that there is a potential for YAP inhibition to elicit unexpected consequences 195 . The WNT hypersensitivity and enhanced stem cell expansion and hyperplasia induced by YAP inhibition was attributed to YAP-dependent cytoplasmic sequestration of the WNT signalling component DVL -a function of YAP that is independent of the transcriptional activity of YAP-TEAD. The growth-promoting effect of YAP deletion may be due to further intestinal differentiation, resulting in an increased number of Paneth cells, which define the stem cell niche and are a major source for WNT ligands 196 . Thus, complete inhibition of YAP may have unintended consequences and result in increased colorectal tumour growth. Desirable effects may thus be best achieved by aiming to reduce the transcriptional activity of the YAP-TEAD complex -for example, by disrupting the YAP-TEAD interaction or by promoting cytoplasmic localization of YAP, rather than completely removing YAP. Indeed, the expression of a dominant negative TEAD2 does not cause overt liver abnormalities 22 . Hence, available evidence supports the notion that selective inhibition of YAP-TEAD function may have therapeutic efficacy with minimal side effects.
Studies using cancer cell assays have provided additional evidence that reducing YAP activity is effective in suppressing tumour growth 190, [197] [198] [199] [200] . Results obtained with human cancer cell lines have demonstrated the efficacy of reducing YAP dosage (by small interfering RNA (siRNA) or short hairpin RNA (shRNA) depletion) in slowing or arresting the growth of tumour cells in vitro or in xenograft assays 190, [197] [198] [199] [200] . YAP knockdown also affects other properties of cancer cells; for example, it makes cancer cells more sensitive to chemotherapeutic reagents 127 , inhibits cancer stem cell formation 137 and reduces their metastatic potential 198, 201 , which suggests that targeting YAP may be effective in modulating various properties of cancer cells that are required for their expansion, survival and spread to distant tissues.
Notably, a recent study has extended the potential for targeting YAP in human cancer to cancers that do not exhibit elevated levels of YAP 55 . Genome-wide screens for shRNA-induced synthetic lethality in a large panel of human cancer cells revealed that many tumour cell lines with activated WNT signalling are particularly sensitive to knockdown of YAP 55 . In this case, YAP forms a transcriptional complex with β-catenin (the nuclear effector of canonical WNT signalling) and TBX5 (a sequencespecific DNA-binding protein); this transcriptional complex is necessary for cell survival 55 . Interfering with the assembly of this complex inhibits tumour cell survival and growth as effectively as knockdown of YAP itself, which suggests that it is the β-catenin-YAP-TBX5 complex that is driving survival, rather than the YAP-TEAD complex (which is presumably also present in these cells). In these cancer cell lines, YAP is constitutively nuclear and is not regulated by cell density, which indicates that there is a non-canonical mode of YAP regulation. Indeed, LATS-independent phosphorylation of YAP by the SRC family kinase YES1 is required for YAP-β-catenin-TBX5 complex formation and for the oncogenic properties of this complex 55 . Thus, this study highlights that sensitivity to YAP inhibition may not always correlate with the levels or activity of YAP, and that TEAD-independent interactions of YAP may be important in some cancer contexts.
In summary, these studies imply that inhibiting the activity of YAP and TAZ may be effective in treating a variety of cancers, that complete inhibition is not required to show therapeutic efficacy, and that the sensitivity of a cancer cell to YAP or TAZ inhibition may not always correlate with levels of YAP or TAZ expression.
The Hippo pathway in repair and regeneration Tissue repair and regeneration often involves stem cell activation and progenitor cell expansion, and an emerging picture is that YAP and TAZ regulate the balance between stem, progenitor and differentiated cells (FIG. 4) . In general, enhanced YAP and/or TAZ activity is associated with stem and progenitor cell expansion that is coupled with inhibition of differentiation, whereas attenuation of YAP and/or TAZ activity tends to have the opposite effect. Examples include stem and progenitor cells of the liver, intestine, pancreas, heart, skin and central nervous system 12, 28, 107, 147, [161] [162] [163] 202 . At present, there is little mechanistic insight into how YAP and TAZ regulate stem cell properties and inhibit their differentiation. However, a recent study by Lian et al. 203 suggests that in murine embryonic stem cells YAP directly binds to the promoters of genes that enhance pluripotency, which suggests that YAP may be a key component of the core pluripotency machinery. It remains to be determined whether this result can be generalized to tissue-specific stem cells in vivo.
In situations where progenitor cell expansion has been observed in vivo by YAP activation, it is not clear whether YAP functions to inhibit differentiation and expand stem cell pools or whether it acts by reprogramming differentiated cells to more primitive and stem cell-like progenitor states. Indeed, in the case of murine embryonic stem cells and induced pluripotent cells, YAP appears to be capable of doing both 203 . Enhanced YAP activity inhibits embryonic stem cell differentiation, whereas inhibition of YAP leads to loss of pluripotency. Similarly, in induced pluripotent cells derived from murine fibroblasts, YAP activity increases during the reprogramming process, and negative regulators of YAP -such as the LATS kinases -act as barriers to reprogramming 204 .
The situation in human induced pluripotent stem cells and embryonic stem cells is similar to that observed in mice; LATS kinases function as negative regulators of reprogramming 204 . However, unlike in the murine setting, in human stem cells this effect appears to be mediated by TAZ 52 . In human embryonic stem cells, TAZ is important for the maintenance of the pluripotent state, whereas YAP is dispensable for this activity. Differences between mouse and human systems are not fully understood but are likely to derive from distinct signalling pathways that regulate pluripotency and reprogramming in murine versus human cells. Taken together, these results suggest that YAP and possibly TAZ promote the reprogramming of differentiated cells as well as the expansion of stem and progenitor cell populations, which are both features that have important applications to regenerative medicine.
An evolutionarily conserved essential function for YAP in tissue regeneration has been described through genetic studies of intestinal epithelial regrowth following injury. Elevated YAP expression is seen in mice treated with dextran sodium sulphate (DSS), a chemical that results in injury and inflammation of the large intestine and initiates a regenerative response 22 . Mice that lack YAP in the colonic epithelium do not show overt defects in intestinal homeostasis but are unable to efficiently undergo a regenerative response following DSS treatment 22 , which is consistent with a role for Hippo signalling in repressing latent regenerative responses that involve stem cell activation. Another study, however, found that conditional elimination of YAP in the intestine promoted tissue regeneration after irradiation and caused hypersensitivity to WNT ligands 195 . The reasons behind the different outcomes in the two studies are unclear at present but may be due to differences in the experimental set-up and the time point of analysis. In any case, these two studies suggest that YAP has growth-promoting as well as growth-suppressing functions, potentially because it directly promotes progenitor cell expansion but also suppresses Paneth cell differentiation, which promotes the survival and self-renewal of intestinal stem cells by producing WNT ligands.
The D. melanogaster intestine also harbours stem cells that are triggered to proliferate in response to tissue damage induced by feeding toxins or pathogens. The D. melanogaster YAP homolog Yorkie is required for this response [24] [25] [26] [27] ; however, unlike in mammals, Yorkie is activated in differentiated enterocytes, and this drives the expression of cytokines that then signal to stem cells and promote their proliferation 24 . Thus, although Yorkie may not be directly involved in controlling intestinal stem cell proliferation in D. melanogaster, it is activated upon tissue damage. Therefore, regulation of the Hippo pathway and activation of YAP in the intestine is involved in driving the regeneration of damaged tissue.
A similar situation may be occurring in the liver, where loss of Hippo signalling results in the expansion of oval cells 141 -a facultative progenitor cell population that contributes to liver repair following hepatocyte injury. In addition, YAP is required for neonatal heart regeneration in mice 28, 29 . Notably, forced overexpression of an activated S127A phospho-site-mutant form of YAP in the adult mouse heart promoted heart regeneration after myocardial infarction 28 . Thus, therapeutic elevation of YAP activity might prove to be beneficial for the restoration of gut, heart, liver and potentially other tissues following injury.
An important effect of the experimental elevation of YAP activity with regard to regeneration is its involvement in promoting the entry of non-dividing cells into the cell cycle. This effect is seen in both the liver 11, 12 and heart 28,29, 147, 161 . These are tissues that are composed of mostly quiescent cells with cellular turnover rates estimated to be in the order of 1 year for human hepatocytes 205 and once in a lifetime for human cardiomyocytes 206 . Although both cell types are normally quiescent, hepatocytes can be readily induced to re-enter the cell cycle and progress through cytokinesis following injury, whereas adult cardiomyocytes do not efficiently undergo cell cycle re-entry and rarely -if at all -undergo cytokinesis. Because of this, the adult liver can regenerate, whereas the heart cannot. Potentially relevant to these observations are the findings that in mouse mutants of core Hippo pathway components (including conditional deletion of Sav1 or combined deletion of Mst1 and Mst2) there is unscheduled hepatocyte proliferation in adult mice [140] [141] [142] [143] and enhanced embryonic cardiomyocyte proliferation 147 . Moreover, overexpression of YAP in adult murine cardiomyocytes induces cell cycle entry and cell division 28, 29, 161 . Hence, transient elevation of YAP activity might prove to be useful for the repair of tissues that do not normally undergo regeneration -such as the heart -and for augmenting the proliferative capability of damaged tissues that normally do undergo regeneration, such as the liver. Altogether, although sustained activation of YAP or TAZ has clear oncogenic potential in several tissues, transient upregulation of YAP or TAZ activity by pharmacological intervention might be useful in situations that require mobilization of stem and progenitor cell populations or even the reprogramming of adult differentiated cells.
Therapeutically targeting the Hippo pathway
The studies described above suggest that manipulation of Hippo pathway activity might be beneficial in cancer prevention and treatment as well as in the expansion of stem cell populations for use in regenerative medicine. Targeting the Hippo pathway as an anticancer therapeutic strategy would aim to suppress YAP and TAZ activity, whereas targeting the Hippo pathway to facilitate the regeneration and reprogramming of adult cells and tissues would aim to elevate YAP and TAZ activity. However, although evidence is mounting to demonstrate that pharmacological manipulation of Hippo signalling as well as YAP and/or TAZ activity would be beneficial, there is a need to develop effective means of manipulating Hippo signalling as well as YAP and TAZ activity in both a sustained and transient manner. In addition, tissuespecific control of YAP and TAZ may become important if chronic and/or long-term whole-body inhibition of YAP and/or TAZ results in deleterious side effects. This may be achieved by targeting individual branches of upstream regulators. Although there is interest and potential in targeting genes and pathways that are downstream of Hippo, YAP and TAZ, such as the AXL receptor kinase 207 , CTGF 208 , epidermal growth factor receptor (EGFR) signalling 209, 210 and others (reviewed in REF. 211 ), below we focus on strategies and small molecules (TABLE 2) that are designed to target Hippo signalling itself by manipulating components of the Hippo pathway.
Kinases. Decades of targeted drug development efforts suggest that kinases and other proteins with enzymatic activity are attractive targets for small-molecule therapeutics 212 . Within the core of the Hippo signalling pathway are two pairs of kinases -MST1 and MST2, and LATS1 and LATS2 -that restrain YAP and TAZ activity. Small-molecule inhibitors of these kinases would thus be predicted to upregulate YAP and TAZ function, which might prove to be beneficial in regenerative medicine applications such as ex vivo stem and progenitor cell expansion and in vivo tissue repair. A small-molecule inhibitor of MST1, called 9E1, has been developed 213 . This molecule inhibits MST activity in vitro and in cultured HeLa cells, as measured by histone H2B phosphorylation in response to apoptosis; however, its effects on YAP and TAZ activity have not yet been reported. 9E1 shows significant -but not complete -selectivity for MST1 over other kinases, and it provides a starting point for the development of more selective MST1 inhibitors. In addition, rational strategies to target kinases are generally effective at identifying lead compounds that can be further developed and refined by traditional medicinal chemistry approaches 214, 215 . Conversely, targeting the MST or LATS kinases for anticancer therapy is more challenging, as small-molecule agonists would be most desirable but there are few options available for the rational design of such agonists. Alternatively, YES1 or HIPK2 may be targeted for cancer therapy in some contexts as these kinases promote YAP activity in some assays; YES1 is required for cell survival and the activation of YAP in β-catenin-active cancer cell lines 55 , and HIPK2 promotes YAP activity in in vitro transcriptional assays 122 . Although there are no reported inhibitors of HIPK2, there is evidence that YES1 inhibition can selectively target cancer cell survival and growth. YES1 phosphorylates YAP, thereby promoting the formation of a YAP-β-catenin-TBX5 transcriptional complex, which is essential for the proliferation of β-catenin-dependent colon cancer cell lines 55 . Notably, the broad-spectrum tyrosine kinase inhibitor dasatinib, which inhibits YES1, was effective in inhibiting the growth of these β-catenin-dependent cell lines in vitro and in inhibiting tumour formation in xenografts, by interfering with the assembly of the YAP-β-catenin-TBX5 complex independently of Hippo pathway modulation 55 . Thus, inhibition of YES1 may be effective in a subset of β-catenin-and YAP-dependent cancers.
The YAP-TEAD and TAZ-TEAD complexes. The most attractive anticancer targets in the Hippo pathway are YAP and TAZ, as they are the key downstream mediators of this pathway. However, pharmacological inhibition of YAP and TAZ is challenging, as these proteins have no known catalytic activity and function by engaging domains that facilitate protein-protein interactions with the upstream kinases LATS1 and LATS2, the 14-3-3 proteins, the polarity proteins AMOT, ZO1 and ZO2, and the TEAD transcription factors. In many cases, the oncogenic properties of YAP and TAZ depend on their interaction with the TEAD proteins 72, 198 . Genetic disruption of this interaction by mutating amino acid residues that are crucial for the formation of the YAP-TEAD complex or the TAZ-TEAD complex abolishes the transforming ability of YAP and TAZ in vitro 49 ; in a mouse model of liver cancer, the expression of a dominant negative form of TEAD2 that sequesters YAP was also shown to abolish the transforming ability of YAP 194 . As the co-crystal structure of the YAP-TEAD complex has been recently determined [216] [217] [218] , it is possible that this detailed structural information can be leveraged to rationally design small-molecule inhibitors of the YAP-TEAD complex by targeting residues that line the YAP-TEAD polypeptide interaction interface. A small-molecule inhibitor of the YAP-TEAD interaction was identified through highthroughput screening, as described below 194 . MASK, WBP2 and Ajuba proteins. Additional components of the Hippo pathway that could be envisioned for targeted anticancer therapy are proteins that are required for YAP and TAZ activity, such as the MASK proteins 118, 119 and WBP2 115, 116 , which directly interact with YAP and TAZ, and Ajuba family proteins, which stimulate LATS activity and thus indirectly inhibit YAP and TAZ 109 . However, all of these are scaffold or regulatory proteins lacking enzymatic activity, which would require targeting . Administration of mitogenic growth factors contained in serum as well as EGF treatment stimulates the nuclear localization of YAP by inhibiting YAP phosphorylation 219, 220 . Based on this observation, Fan et al. 219 screened small-molecule inhibitors of kinases and phosphatases that act downstream of EGF signalling and found that inhibitors of PI3K and pyruvate dehydrogenase kinase 1 (PDK1), but not inhibitors of AKT, were effective in blocking the nuclear localization of YAP induced by EGF and lysophosphatidic acid. Mechanistically, PDK1 physically associates with the core Hippo pathway kinase complex and this complex dissociates in response to EGF signalling, thereby resulting in YAP activation 219 . Thus, inhibitors of PI3K and PDK1 may be effective in reducing YAP activity in cells with an intact Hippo signalling pathway that have elevated EGFR and/or reduced PTEN function.
GPCR signalling. Three recent reports have linked GPCRs to Hippo pathway regulation [102] [103] [104] . Lysophosphatidic acid, sphingosine-1-phosphate and thrombin were found to signal through Gα 12/13 -coupled GPCRs to stimulate YAP nuclear localization and activity [102] [103] [104] . Importantly, representatives of many different GPCR subgroups affect YAP, which demonstrates a general function of GPCRs in YAP regulation 102 . GPCRs that act through Gα 12/13 , Gα q/11 or Gα i/o proteins stimulate YAP, whereas Gα scoupled receptors have the opposite effect 102 . GPCRs regulate YAP via RHO GTPases and the actin cytoskeleton to inhibit LATS kinases independently of MST kinases, causing dephosphorylation and nuclear accumulation of YAP [102] [103] [104] . Agonists of Gα s -coupled receptors -such as adrenaline, glucagon and the dopamine receptor agonist dihydrexidine -result in enhanced YAP phosphorylation and inactivation 102, 221 . Importantly, GPCR agonists such as adrenaline also affect YAP phosphorylation in vivo, causing an increase in YAP phosphorylation in the heart of injected mice 102 . These results therefore indicate that YAP activity can be modulated with drugs that affect GPCR signalling, although it remains to be determined which agonists or antagonists will be effective in therapeutic applications.
F-actin.
The identification of F-actin as an important regulator of YAP and TAZ localization and activity uncovers new opportunities for the modulation of Hippo signalling with small molecules. The F-actin destabilizers cytochalasin D, latrunculin A and latrunculin B, as well as treatment with the non-muscle myosin II inhibitor blebbistatin, the myosin light-chain kinase inhibitor ML-7, the RHO inhibitor botulinum toxin C3 and the RHO kinase inhibitor Y27632 all cause nuclear export of YAP and TAZ 97, [99] [100] [101] . These results suggest that drugs targeting F-actin and its modulators may also be effective in modulating YAP and TAZ activity in vivo. This approach is complicated, however, by the fact that the actin cytoskeleton is not a Hippo pathway-specific signal transduction component but is instead required for many basic cellular functions. Nevertheless, non-lethal levels of actin modulators may enhance the effects of other drugs that target the Hippo pathway via different mechanisms.
High-throughput screening approaches. An attractive approach to identify small-molecule inhibitors and activators of Hippo signalling is through the application of cell-based high-throughput screening. Indeed, when approximately 3,300 US Food and Drug Administration (FDA)-approved drugs were screened for inhibitors of the transcriptional activity of YAP, 71 hits were identified including several porphyrin compounds 194 . One of these compounds, verteporfin, which is currently used as a photosensitizer in the treatment of macular degeneration, was effective in vivo in delaying tumour progression in an Nf2-depleted mouse model of liver cancer and in suppressing liver overgrowth caused by the overexpression of YAP; these results were observed following repeated administration of verteporfin during the development of the cancer phenotype 194 . Verteporfin was found to bind to YAP in vitro and to inhibit the interaction of YAP with TEAD 194 . Although these data are exciting, further studies will be needed to determine whether verteporfin is effective in other in vitro and in vivo cancer models and also whether it is effective in the treatment of established cancers. In addition, verteporfin has a relatively low affinity for YAP (at the micromolar level), and so higher-affinity derivatives may be required.
In another cell-based screen of 48 drugs for the identification of inhibitors of YAP nuclear localization, dobutamine -a G protein-coupled β-adrenergic receptor agonist that is clinically used to treat acute heart failure -was identified as being effective in preventing the nuclear accumulation of YAP and YAP-mediated transcriptional activation in osteoblastoma and HEK293 cells 222 . Dobutamine treatment induced cytoplasmic translocation of YAP and phosphorylation of Ser127, the main LATS phosphorylation site. Phosphorylation of this site was required for the effect of dobutamine, although it appeared to be phosphorylated by a kinase other than LATS 222 . Similarly to other GPCRs, dobutamine-mediated activation of the β-adrenergic receptor is likely to act through a pathway that involves RHO GTPases and F-actin [102] [103] [104] .
Open questions and future challenges
The Hippo pathway -and in particular the YAP-TEAD and TAZ-TEAD complexes -is an emerging anticancer target, and mounting evidence from mouse models as well as tissue culture assays indicates that targeting the Hippo pathway is effective in preventing disease and in counteracting the cellular mechanisms that promote oncogenic transformation. Although less appreciated, there is also considerable potential for the application of small molecules that transiently activate the YAP-TEAD and TAZ-TEAD complexes to promote stem cell expansion and tissue repair following injury.
Research over the past decade has identified a complex network of regulatory components within the Hippo pathway and established robust assays through which the activity of this pathway can be measured. These findingsnow provide a rich landscape for the identification of small-molecule modulators of the Hippo pathway; various pharmacological modulators of Hippo signalling have already been discovered. The challenges now are to determine whether these drugs will be therapeutically useful, which combinations will be the most effective and in what disease contexts they should be applied. Reflecting the complex regulation of the Hippo signalling pathway, these small molecules affect several pathway components and branches. However, many of these compounds do not specifically target components of the Hippo pathway and therefore another challenge is to develop novel modulators that specifically target the Hippo pathway, particularly the activity of the YAP-TEAD and TAZ-TEAD complexes.
As many of the pathway components are adaptor proteins that may be difficult to target, it will be important to discover additional membersof the Hippo pathway, especially those that directly affect YAP and TAZ, which may lead to the identification of better drug targets. For example, it has recently been found that SET7-dependent lysine monomethylation of YAP is important for cytoplasmic retention 223 , which suggests that the identification and selective inhibition of YAP protein demethylases could be a novel approach for modulating YAP activity. Similarly, p300/CBP (CREBbinding protein) mediates the acetylation of YAP and sirtuin 1 (SIRT1) mediates the deacetylation of YAP 224, 225 , which indicates that modulators of the acetylation cycle may be used to modulate YAP activity. Another challenge is to decipher how YAP and TAZ are deregulated in cancer as this will be crucial for determining which components in the pathway should be targeted.
In principle, targeting the Hippo pathway for applications in regenerative medicine may be more easily accomplished as the core of the pathway contains two kinases. It will thus be interesting to develop and test inhibitors of the MST and LATS kinases -such as the compound 9E1 -for transient stimulation of growth and regeneration of tissues following injury and in applications where stem and progenitor cell expansion is desired.
Although most attention has focused on smallmolecule-mediated manipulation of YAP and TAZ activity by controlling the subcellular localization of YAP and TAZ or their ability to form complexes with TEADs, there are other avenues for the pharmacological manipulation of these proteins that warrant further investigation. For example, YAP and TAZ stability is controlled by phosphorylation-induced protein degradation 68, 69 , and small molecules that enhance the turnover of YAP and TAZ would be expected to reduce the nuclear transcriptional activities of these proteins. Finally, not all components of the Hippo pathway are required in all tissues, and the pathway has tissue-specific regulatory mechanisms. Targeting such tissue-specific regulators provides opportunities to manipulate the Hippo pathway in specific cells, which may help in reducing toxicity and increasing therapeutic value.
In conclusion, although studies aimed at targeting the Hippo pathway for therapeutic purposes are still in their infancy, promising preclinical genetic and pharmacological results have already been documented in the literature. We anticipate that the full potential of harnessing the Hippo pathway in the prevention and treatment of human disease will soon be realized. 
